Editas Inks Three Licensing Deals for Genome-Editing Technologies | GenomeWeb

NEW YORK (GenomeWeb) – Editas Medicine announced today that it has signed a licensing deal with Massachusetts General Hospital for intellectual property related to the use of CRISPR/Cas9 and TALEN genome-editing technologies for human and veterinary therapeutic applications, as well as broad agricultural use.

Separately, Editas said that it had struck similar deals with Duke University, Harvard University, and the Broad Institute for CRISPR/Cas9 and TALENs IP for the development of human therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.